Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for securities fraud, alleging that the company made materially false statements and failed to disclose adverse facts about its business and operations during the class period from February 21, 2025, to August 28, 2025 [1][5]. Summary by Sections Company Disclosures - On July 22, 2025, Telix disclosed it received a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures related to prostate cancer therapeutic candidates, leading to a stock price drop of $1.70, or 10.4%, closing at $14.58 on July 23, 2025 [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA concerning its Biologics License Application (BLA) for TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package. This announcement caused the stock price to fall by $1.95, or 16.1%, closing at $10.15 on the same day [4]. Allegations in the Lawsuit - The lawsuit alleges that throughout the class period, Telix's management made materially false and misleading statements and failed to disclose critical adverse facts, including: 1. Overstating the progress made on prostate cancer therapeutic candidates [5]. 2. Overstating the quality of Telix's supply chain and partners [5]. 3. Positive statements about the company's business and prospects were materially misleading and lacked a reasonable basis [5].
Law Offices of Howard G. Smith Encourages Telix Pharmaceuticals Limited (TLX) Shareholders To Inquire About Securities Fraud Class Action